drugset / Trial / NCT01748851
XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to identify the non-inferiority of the combination therapy of Capecitabine and Oxaliplatin compared with the combination therapy of Fluorouracil/Folinic acid and Oxaliplatin in patients with advanced gastric cancer.
Timeline
- Start
- 2012-12
- Primary completion
- 2014-09
- Completion
- 2014-09
Outcome
Outcome not reported
Stopped (Enrollment): “Poor enrollment of patients”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Leucovorin | Small molecule | 400 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Comparator | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Comparator | fluorouracil | Small molecule | 1200 mg/m2 | Intravenous |